<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00291603</url>
  </required_header>
  <id_info>
    <org_study_id>2005-192</org_study_id>
    <nct_id>NCT00291603</nct_id>
  </id_info>
  <brief_title>Short Term Effects of FX Dialysers on QOL and Inflammation</brief_title>
  <official_title>Short-Term Effects of the FX-Class of Haemodialyser on Quality of Life and Inflammatory Markers in Stable Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sir Charles Gairdner Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sir Charles Gairdner Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      The new hollow fibre FX-class of dialysers (Fresenius Medical Care, Bad Homburg, Germany)&#xD;
      features a number of technological improvements that may benefit the patient. This includes&#xD;
      the use of the advanced high-flux polysulfone membrane, HelixoneÂ®, which has an extremely&#xD;
      high endotoxin retaining capability. Theoretically leading to reduced systemic inflammation&#xD;
      in the patient, which is an important factor for morbidity and mortality with dialysis.&#xD;
&#xD;
      The dialysis membrane is the first to be manufactured using membrane-spinning procedures&#xD;
      (nano-controlled spinning technology) that enables the membrane to be modulated at the&#xD;
      nano-scale level. The resultant membrane is able to extremely efficiently remove middle&#xD;
      molecules, along with minimal loss of albumin.&#xD;
&#xD;
      These features may lead to improved patient outcomes, including reduced systemic inflammation&#xD;
      and improved quality of life.&#xD;
&#xD;
      Aims:&#xD;
&#xD;
        1. To assess the short-term effects of the FX-class Dialyser on quality of life in stable&#xD;
           haemodialysis patients&#xD;
&#xD;
        2. To assess the short-term effects of the FX-class Dialyser on inflammatory markers in&#xD;
           stable haemodialysis patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods Patient selection All patients in the Joondalup Health Campus satellite dialysis unit&#xD;
      will be invited to participate in this study.&#xD;
&#xD;
      Inclusion criteria -&#xD;
&#xD;
        1. Age &gt;18years&#xD;
&#xD;
        2. Able to provide informed consent&#xD;
&#xD;
        3. On haemodialysis for 3 months&#xD;
&#xD;
      Exclusion criteria -&#xD;
&#xD;
        1. Active inflammatory, infective or neoplastic process within the last 1 month&#xD;
&#xD;
        2. Active major psychiatric condition&#xD;
&#xD;
        3. Currently on haemodiafiltration as haemodialysis modality&#xD;
&#xD;
      Design This study will involve an unblinded, cross-over design, with patients being&#xD;
      randomised upon entry into one of 2 groups. The 2 groups will be - 1. HF80 dialyser (this is&#xD;
      the best of the currently used dialysers and therefore no participant will require a&#xD;
      reduction in their dialysis during this trial); and 2. FX dialyser. Patients will have&#xD;
      baseline tests performed prior to intervention and then repeated after 3 months. At 3 months,&#xD;
      patients will then cross-over into the other group and tests repeated after a further 6&#xD;
      months.&#xD;
&#xD;
      Due to the nature of the intervention, blinding will not be practical. The cross-over design&#xD;
      will allow maximum power for this fixed and relatively small dialysis population (~50&#xD;
      patients).&#xD;
&#xD;
      Independent variables -&#xD;
&#xD;
        1. Dialysis prescription on enrolment&#xD;
&#xD;
           a. Including dialyser type (biocompatibility)&#xD;
&#xD;
        2. Adequacy of dialysis&#xD;
&#xD;
             1. Urea reduction ratio&#xD;
&#xD;
             2. Kt/V&#xD;
&#xD;
        3. Anaemia&#xD;
&#xD;
             1. Including iron studies&#xD;
&#xD;
             2. Including erythropoietin usage&#xD;
&#xD;
        4. Calcium phosphate balance&#xD;
&#xD;
           a. Including Parathyroid hormone levels&#xD;
&#xD;
        5. Serum albumin&#xD;
&#xD;
      Outcome markers -&#xD;
&#xD;
        1. Quality of Life (i) KD-QOL - this is a standardised quality of life questionnaire&#xD;
           designed and validated for dialysis patients, that will be readily comparable to other&#xD;
           studies.&#xD;
&#xD;
           (ii) Feeling thermometer&#xD;
&#xD;
        2. Inflammatory markers (i) High sensitivity c-reactive protein (ii) IL-6 (iii) White cell&#xD;
           count.&#xD;
&#xD;
      Statistical analysis:&#xD;
&#xD;
      Quality of life measures and inflammatory markers will be analysed using paired t-test after&#xD;
      normality demonstrated. Simple and multiple linear regression analysis will then be performed&#xD;
      to examine associations between independent variables with changes in the outcome variables.&#xD;
      STATA 8.2 will be used to assist with the analysis&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>KD-QOL</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Feeling Thermometer</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>IL-6</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TNF-alpha</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hs-CRP</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>white cell count</measure>
  </secondary_outcome>
  <enrollment>50</enrollment>
  <condition>Kidney Failure, Chronic</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FX-class of dialyser</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt;18years&#xD;
&#xD;
          2. Able to provide informed consent&#xD;
&#xD;
          3. On haemodialysis for 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active inflammatory, infective or neoplastic process within the last 1 month&#xD;
&#xD;
          2. Active major psychiatric condition&#xD;
&#xD;
          3. Currently on haemodiafiltration as haemodialysis modality&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil C Boudville, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Western Australia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Joondalup Health Campus Satellite Dialysis Unit</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <study_first_submitted>February 13, 2006</study_first_submitted>
  <study_first_submitted_qc>February 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2006</study_first_posted>
  <last_update_submitted>April 24, 2007</last_update_submitted>
  <last_update_submitted_qc>April 24, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2007</last_update_posted>
  <keyword>dialysis</keyword>
  <keyword>Renal Dialysis</keyword>
  <keyword>inflammation</keyword>
  <keyword>quality of life</keyword>
  <keyword>End Stage Kidney Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

